Abstract
Background
Cancer cachexia is the wasting condition that is often seen in advanced stage cancer patients. This wasting is largely attributable to a systemic and progressive loss of skeletal muscle mass that greatly hinders performance of normal daily activities, resulting in reduced quality of life. Moreover, it negatively influences the prognosis of cancer patients. A general consensus in the field is that the loss of muscle mass is due both to an increase in protein degradation and a decrease in protein synthesis. Recent studies using preclinical models for studying cachexia have been useful in identifying the contribution of inflammatory cytokines (e.g. tumor necrosis factor-α and Interleukin-6), and myostatin receptors (e.g. the type IIB activin receptor) to cachexia development, and have led to several clinical trials. However, many questions remain about the molecular mechanisms thought to play a role in the development of cachexia.
Methods
We conducted a literature search using search engines, such as PubMed and Google Scholar to identify publications within the cancer cachexia field.
Results
We summarized our current knowledge of: 1) the driving mechanisms of cancer cachexia, 2) the preclinical models available for studying the condition, and 3) the findings of recent clinical trials.
Conclusion
Cancer cachexia is a complex and variable condition that currently has no standard effective therapeutic treatment. Further studies are desperately needed to better understand this condition and develop effective combination treatments for patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Al-Majid S, Waters H (2008). The biological mechanisms of cancerrelated skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs, 10(1): 7–20
Argilés J M, Busquets S, Stemmler B, López-Soriano F J (2014). Cancer cachexia: understanding the molecular basis. Nat Rev Cancer, 14 (11): 754–762
Aulino P, Berardi E, Cardillo V M, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini E P, Baldi A, Faiola F, Adamo S, Coletti D (2010). Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer, 10(1): 363
Bayliss T J, Smith J T, Schuster M, Dragnev K H, Rigas J R (2011). A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther, 11(12): 1663–1668
Bennani-Baiti N, Walsh D (2009). What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb, 39 (3): 257–262
Bilodeau P A, Coyne E S, Wing S S (2016). The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation. Am J Physiol Cell Physiol, 311(3): C392–C403
Bing C, Taylor S, Tisdale M J, Williams G (2001). Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem, 79 (5): 1004–1012
Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris L G, Zimmers T A (2012). JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab, 303(3): E410–E421
Bowen T S, Schuler G, Adams V (2015). Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle, 6(3): 197–207
Carson J A, Baltgalvis K A (2010). Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev, 38(4): 168–176
Choi E, Carruthers K, Zhang L, Thomas N, Battaglino R A, Morse L R, Widrick J J (2013). Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep, 1(6): e00144
Consul N, Guo X, Coker C, Lopez-Pintado S, Hibshoosh H, Zhao B, Kalinsky K, Acharyya S (2016). Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study. Clin Med Insights Oncol, 10: 83–94
Crawford J, Prado C M, Johnston M A, Gralla R J, Taylor R P, Hancock M L, Dalton J T (2016). Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep, 18(6): 37
Deboer M D (2009). Animal models of anorexia and cachexia. Expert Opin Drug Discov, 4(11): 1145–1155
Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura L A (2012). Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients. J Hosp Palliat Nurs, 14(6): 397–402
Dobs A S, Boccia R V, Croot C C, Gabrail N Y, Dalton J T, Hancock M L, Johnston M A, Steiner M S (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol, 14 (4): 335–345
Eley H L, Russell S T, Tisdale M J (2007). Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J, 407 (1): 113–120
Fearon K, Strasser F, Anker S D, Bosaeus I, Bruera E, Fainsinger R L, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos V E (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 12(5): 489–495
Fukawa T, Yan-Jiang B C, Min-Wen J C, Jun-Hao E T, Huang D, Qian C N, Ong P, Li Z, Chen S, Mak S Y, Lim W J, Kanayama H O, Mohan R E,Wang R R, Lai J H, Chua C, Ong H S, Tan K K, Ho Y S, Tan I B, Teh B T, Shyh-Chang N (2016). Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med, 22(6): 666–671
Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K, Petruzelka L, Apte R N, Mohanty P, Stecher M, Simard J, de Gramont A (2017). MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 18(2): 192–201
Islam-Ali B, Khan S, Price S A, Tisdale M J (2001). Modulation of adipocyte G-protein expression in cancer cachexia by a lipidmobilizing factor (LMF). Br J Cancer, 85(5): 758–763
Jatoi A, Dakhil S R, Nguyen P L, Sloan J A, Kugler J W, Rowland K M Jr, Soori G S, Wender D B, Fitch T R, Novotny P J, Loprinzi C L (2007). A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer, 110(6): 1396–1403
Karayiannakis A J, Syrigos K N, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res, 21(2B): 1355–1358
Li Y P, Reid M B (2000). NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol, 279(4): R1165–R1170
Lok C (2015). Cachexia: The last illness. Nature, 528(7581): 182–183
Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, Riccobon A, Derni S, Pallotti G, Amadori D (1997). Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer, 5(2): 130–135
McLean J B, Moylan J S, Andrade F H (2014). Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes. Front Physiol, 5: 503
Monitto C L, Dong SM, Jen J, Sidransky D (2004). Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res, 10(17): 5862–5869
Mueller T C, Bachmann J, Prokopchuk O, Friess H, Martignoni M E (2016). Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia–can findings from animal models be translated to humans? BMC Cancer, 16(1): 75
Na Y J, Baek H S, Ahn S M, Shin H J, Chang I S, Hwang J S (2007). [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol, 74(5): 780–786
Narsale A A, Carson J A (2014). Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care, 8(4): 321–327
National Cancer Institute (2011). Tackling the Conundrum of Cachexia in Cancer. Accessed in 2018, from https://www.cancer.gov/aboutcancer/ treatment/research/cachexia.
Onesti J K, Guttridge D C (2014). Inflammation based regulation of cancer cachexia. BioMed Res Int, 2014: 168407
Pagan J, Seto T, Pagano M, Cittadini A (2013). Role of the ubiquitin proteasome system in the heart. Circ Res, 112(7): 1046–1058
Pasut A, Jones A E, Rudnicki M A (2013). Isolation and culture of individual myofibers and their satellite cells from adult skeletal muscle. J Vis Exp, (73): e50074
Patel H J, Patel B M (2017). TNF-a and cancer cachexia: Molecular insights and clinical implications. Life Sci, 170: 56–63
Penafuerte C A, Gagnon B, Sirois J, Murphy J, MacDonald N, Tremblay M L (2016). Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br J Cancer, 114(6): 680–687
Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G, Zechner R, Wagner E F (2014). A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab, 20(3): 433–447
Petruzzelli M, Wagner E F (2016). Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev, 30(5): 489–501
Porporato P E (2016). Understanding cachexia as a cancer metabolism syndrome. Oncogenesis, 5(2): e200
Puppa M, Narsale A, Rose-John S, Carson J (2014). Trans IL-6 signaling and suppressed muscle protein synthesis with cancer. FASEB J, 28(1)
Russell S T, Sanders P M, Tisdale M J (2006). Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett, 231(2): 290–294
Sakuma K, Yamaguchi A (2012). Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle, 3(2): 77–94
Sandri M (2013). Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol, 45(10): 2121–2129
Shiono M, Huang K, Downey R J, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K,Wei Y, Zhang Y, Borczuk A C, Inoue A, Halmos B, Acharyya S (2016). An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Med, 5(9): 2641–2648
Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A (2013). Cancer cachexia–pathophysiology and management. J Gastroenterol, 48(5): 574–594
Temel J S, Abernethy A P, Currow D C, Friend J, Duus E M, Yan Y, Fearon K C (2016). Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol, 17(4): 519–531
Waning D L, Mohammad K S, Reiken S, Xie W, Andersson D C, John S, Chiechi A, Wright L E, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi M S, Witzmann F A, Zhen G,Wang X, Cao X, Roodman G D, Marks A R, Guise T A (2015). Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med, 21(11): 1262–1271
Wieland B M, Stewart G D, Skipworth R J, Sangster K, Fearon K C, Ross J A, Reiman T J, Easaw J, Mourtzakis M, Kumar V, Pak B J, Calder K, Filippatos G, Kremastinos D T, Palcic M, Baracos V E (2007). Is there a human homologue to the murine proteolysisinducing factor? Clin Cancer Res, 13(17): 4984–4992
Winbanks C E, Murphy K T, Bernardo B C, Qian H, Liu Y, Sepulveda P V, Beyer C, Hagg A, Thomson R E, Chen J L,Walton K L, Loveland K L, McMullen J R, Rodgers B D, Harrison C A, Lynch G S, Gregorevic P (2016). Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci Transl Med, 8(348): 348ra98
Wu C, Fernandez S A, Criswell T, Chidiac T A, Guttridge D, Villalona-Calero M, Bekaii-Saab T S (2013). Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas, 42(5): 813–818
Yoshida T, Galvez S, Tiwari S, Rezk BM, Semprun-Prieto L, Higashi Y, Sukhanov S, Yablonka-Reuveni Z, Delafontaine P (2013). Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem, 288(33): 23823–23832
Zhou X, Wang J L, Lu J, Song Y, Kwak K S, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet W S, Lacey D L, Goldberg A L, Han H Q (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell, 142(4): 531–543
Acknowledgments
This work is directly supported by National Cancer Institute Grants CA163124 (Y. Shiozawa), Department of Defense (W81XWH-14-1-0403 and W81XWH-17-1-0541, Y. Shiozawa), the Wake Forest Baptist Comprehensive Cancer Center Internal Pilot Funding (Y. Shiozawa), and the Wake Forest School of Medicine Internal Pilot Funding (Y. Shiozawa). Y. Shiozawa is supported as the Translational Research Academy which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001420. This work is also supported by the National Cancer Institute’s Cancer Center Support Grant award number P30CA012197 issued to the Wake Forest Baptist Comprehensive Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Widner, D.B., Files, D.C., Weaver, K.E. et al. Preclinical and clinical studies on cancer-associated cachexia. Front. Biol. 13, 11–18 (2018). https://doi.org/10.1007/s11515-018-1484-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11515-018-1484-4